Background illustration for clinical trials search

Paid Clinical Trials Daytona Beach

Discover 861 paid clinical trials in Daytona Beach, Florida. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 861

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

for

Advanced Non-Small Cell Lung Cancer,

Location: Orlando FL, Jacksonville FL, Tampa FL, Bay Pines FL,

Sponsor: Mirati Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT04613596

Phase2, Phase3, Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for

Ganglioneuroblastoma, Nodular, Neuroblastoma

Location: Orlando FL, Gainesville FL, Jacksonville FL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0 - 30

Code: NCT06172296

Phase3, Recruiting

Project: Every Child for Younger Patients With Cancer

for

Adrenal Gland Pheochromocytoma, Carcinoma In Situ,

Location: Orlando FL, Gainesville FL, Jacksonville FL, Tampa FL,

Sponsor: Children's Oncology Group

Sex: All

Age: 0 - 25

Code: NCT02402244

Recruiting

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for

Acute Myeloid Leukemia

Location: Orlando FL, Gainesville FL, Jacksonville FL, Tampa FL,

Sponsor: Children's Oncology Group

Sex: All

Age: 0 - 21

Code: NCT04293562

Phase3, Recruiting

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for

Hematopoietic and Lymphatic System Neoplasm,

Location: Orlando FL, Gainesville FL, Jacksonville FL, Tampa FL,

Sponsor: Children's Oncology Group

Sex: Female

Age: 0 - 39

Code: NCT06513962

Phase3, Recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

for

Acute Leukemia of Ambiguous Lineage,

Location: Orlando FL, Gainesville FL, Jacksonville FL, Tampa FL,

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0 - 1

Code: NCT06317662

Phase2, Recruiting

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for

Colorectal Neoplasms

Location: Orlando FL, St. Petersburg FL, West Palm Beach FL,

Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06662786

Phase3, Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

for

Squamous Cell Carcinoma of Head and Neck

Location: Orlando FL, St. Petersburg FL, West Palm Beach FL,

Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT07276399

Phase3, Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for

Endometrial Cancer

Location: Orlando FL, Gainesville FL, St. Petersburg FL,

Sponsor: Merck Sharp & Dohme LLC

Sex: Female

Age: 18+

Code: NCT06952504

Phase3, Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

for

Metastatic Head-and-neck Squamous-cell Carcinoma,

Location: Orlando FL, Tampa FL, Charleston SC, Atlanta GA,

Sponsor: AVEO Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT06064877

Phase3, Recruiting

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

for

Biliary Tract Cancer

Location: Orlando FL, Richmond VA, Louisville KY, New York NY,

Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06282575

Phase3, Recruiting

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

for

Urothelial Carcinoma Bladder,

Location: Orlando FL, Tampa FL, Miami FL, Glen Burnie MD,

Sponsor: Aktis Oncology, Inc.

Sex: All

Age: 18+

Code: NCT07020117

Phase1, Recruiting

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

for

Advanced Solid Tumor

Location: Orlando FL, Ocala FL, Gainesville FL, Hollywood FL,

Sponsor: OncoC4, Inc.

Sex: All

Age: 18+

Code: NCT06635785

Phase1, Phase2, Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for

Breast Cancer

Location: Orlando FL, Jacksonville FL, Palm Bay FL, Lakeland FL,

Sponsor: Stemline Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06492616

Phase3, Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for

Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis,

Location: Orlando FL, Jacksonville FL, Tampa FL, Miami FL,

Sponsor: Kartos Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06479135

Phase3, Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

for

Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult,

Location: Orlando FL, Atlanta GA, Nashville TN,

Sponsor: NiKang Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06586957

Phase1, Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for

Colorectal Neoplasms

Location: Orlando FL, St. Petersburg FL, West Palm Beach FL,

Sponsor: Janssen Research & Development, LLC

Sex: All

Age: 18+

Code: NCT06750094

Phase3, Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for

Large B-cell Lymphoma

Location: Orlando FL, Tampa FL, Miami FL, Augusta GA,

Sponsor: Allogene Therapeutics

Sex: All

Age: 18+

Code: NCT06500273

Phase2, Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

for

Small Cell Lung Cancer

Location: Orlando FL, Miami FL, Lexington KY, Germantown TN,

Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06203210

Phase3, Recruiting

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

for

Lymphoma

Location: Orlando FL, Philadelphia PA, Houston TX,

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06624085

Phase1, Recruiting

Paid Clinical Trials Daytona Beach

Filter results

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Project: Every Child for Younger Patients With Cancer

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

Interested in new trials?

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma